查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1179952

2023-2030 年全球基底細胞癌治療市場

Global Basal Cell Carcinoma Treatment Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概覽

在預測期內 (2023-2030)，全球基底細胞癌治療市場規模預計將以 9.4% 的複合年增長率增長。

基底細胞癌 (BCC) 是一種皮膚癌。 基底細胞癌是基底細胞癌的起點，基底細胞癌是一種皮膚細胞，當舊細胞退化時會產生新的皮膚細胞。 它可以有多種形式，但最常見的是皮膚上的半透明小腫塊。 此外，它更容易發生在頭部和頸部等陽光照射部位，發病率往往高於其他皮膚部位。

市場動態

推動全球基底細胞癌治療市場的主要因素是隨著皮膚癌的流行和基底細胞癌治療產品的批准，預計市場將擴大。 人們越來越注重健康，這推動了市場的增長。

基底細胞癌治療產品的批准有望推動市場增長。

角質形成細胞腫瘤（俗稱非黑色素瘤皮膚惡性腫瘤）的發病率在世界範圍內呈上升趨勢，基底細胞癌和鱗狀細胞癌是最常見的類型。 所有類型的癌症都需要手術，但有些病例會進展或轉移，需要靶向治療。 基底細胞癌受hedgehog信號系統的影響很大，其抑制是局部晚期和轉移性基底細胞癌新療法的關鍵。 使用 FDA 批准的藥物進行的臨床前和臨床研究提出了化學預防和治療基底細胞瘤的新應用。 此外，阻斷 Hh 通路的新型化合物顯示出前景，並與其他藥物聯合使用，可能為這種最常見的惡性腫瘤提供非手術治療。

市場上的主要參與者正集中精力獲得治療基底細胞癌的產品批准，這將在預測期內推動全球基底細胞癌市場的增長。然後預測。 例如，2021年6月，歐盟委員會（EC）對總部位於巴黎的法國跨國製藥公司賽諾菲（Sanofi）進行刺蝟通路抑製劑（HHI）批准使用再生元（Regeneron）的PD-1抑製劑ribtayo (cemiplimab) 用於治療患有或耐受性差的局部晚期或轉移性基底細胞癌 (BCC) 的成人。

預計熟練專業人員的短缺會阻礙市場增長。

在預測期內，全球基底細胞癌治療市場的發展可能會受到對不了解該疾病可用治療方案的更多熟練專業人員的需求的限制。

COVID-19 影響分析

全球基底細胞癌治療市場已受到 COVID-19 的不利影響。 越來越多的癌症患者對診斷數量產生了負面影響，並因此阻礙了世界治療。 特別是在大流行初期，由於醫療機構高度重視遏制 COVID-19 大流行，新病例發現減少，診斷程序數量顯著減少，皮膚病變活檢等程序減少。 .

此外，COVID-19 疫情在許多方面給全球基底細胞癌市場的行業參與者帶來嚴峻挑戰。 運輸不規範造成的最大問題之一是製造藥物配方所需原材料的可用性。 此外，由於患有 COVID-19 和其他危及生命的疾病的患者數量不斷增加，分銷商正目睹零售商對其產品的不可預測的需求。

內容

第一章研究方法與範圍

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

第四章市場動態

  • 市場影響因素
    • 司機
      • 市場預計會因皮膚癌的增加而擴大
      • 用於治療基底細胞癌的產品獲批
    • 約束因素
      • 缺乏熟練的專業人員，這是一個市場瓶頸
    • 商機
    • 影響分析

第五章行業分析

  • 波特的五力分析
  • 供應鏈分析
  • 定價分析
  • 監管分析

第 6 章 COVID-19 分析

  • COVID-19 市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

第 7 章按治療類型分類

  • 手術治療
    • 手術切除
    • 電拋光/切割 ED&C
    • 莫氏手術和冷凍手術
  • 藥物治療
      • 局部治療
      • 高級藥物
      • 其他
  • 治愈
      • 放射治療
      • 光動力療法
      • 激光治療

最終用戶第 8 章

  • 醫院
  • 專科診所
  • 其他

第9章按地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第10章競爭格局

  • 主要發展和戰略
  • 公司股票分析
  • 產品基準
  • 值得關注的主要公司名單

第11章公司簡介

  • Sun Pharmaceutical Industries, Inc
    • 公司簡介
    • 產品組合和說明
    • 主要亮點
    • 財務摘要
  • Sun Pharmaceuticals Ltd.
  • Merck & Co., Inc.
  • Valeant Pharmaceuticals International, Inc.
  • Regeneron Pharmaceuticals Inc
  • Hoffmann-La Roche Ltd.
  • Mylan N.V.
  • Perrigo Company
  • Strides Arcolab Ltd
  • AiViva Bio Pharma, Inc
  • Sanofi

第 12 章全球基底細胞癌治療市場-DataM

簡介目錄
Product Code: DMPH11

Market Overview

The global basal cell carcinoma treatment market size was valued at US$ XX million in 2023 and is estimated to reach US$ XX million by 2030, growing at a CAGR of 9.4% during the forecast period (2023-2030).

Basal cell carcinoma (BCC) is a type of skin cancer. Basal cells, a type of skin cell that creates new skin cells as old ones degenerate, are where basal cell cancer starts. Although it can take numerous forms, basal cell carcinoma frequently manifests as a small, slightly translucent lump on the skin. The skin on the head and neck, as well as other sun-exposed locations, tends to develop basal cell carcinoma more frequently than other skin types.

Market Dynamics

The major factors driving the global basal cell carcinoma treatment market are the market is predicted to grow as skin cancers become more common and product approval for basal cell carcinoma therapy. People are becoming more mindful of their health, which helps the market grow.

Product approval for basal cell carcinoma therapy is expected to drive the market's growth.

The frequency of keratinocyte tumors, commonly known as non-melanoma skin malignancies, is rising worldwide, with basal cell carcinoma and squamous cell carcinoma being the most prevalent types. Even though surgery is the preferred course of action for both cancers, some cases can proceed to an advanced or metastatic stage, necessitating targeted therapy. The hedgehog signaling system heavily influences basal cell carcinoma, and its suppression is the key to new therapeutic approaches for both locally progressed and metastatic basal cell carcinoma. Preclinical and clinical research using already FDA-approved medications point to new applications for BCC chemoprevention and therapy. Additionally, novel chemical compounds that block the Hh pathway exhibit promise and may offer a nonsurgical treatment for this most prevalent malignancy when combined with other medications.

Then, the major players in the market are concentrating on getting their products approved for the treatment of basal cell carcinoma, which is anticipated to propel the growth of the global basal cell carcinoma market during the forecast period. For instance, in June 2021, The European Commission (EC) authorized Sanofi, a French multinational pharmaceutical company with its headquarters in Paris, to use Regeneron's PD-1 inhibitor Libtayo (cemiplimab) to treat adults with locally advanced or metastatic basal cell carcinoma (BCC) who have progressed on or become intolerable to a hedgehog pathway inhibitor (HHI).

Lack of skilled experts is expected to hamper the market's growth.

The development of the global basal cell carcinoma treatment market over the forecast period may be constrained by a need for more skilled experts who are ignorant of the available treatment options for this illness.

COVID-19 Impact Analysis

The global market for basal cell carcinoma therapeutics was adversely affected by the COVID-19. The increase in cancer cases had a negative impact on the number of diagnoses and thus hindered global Therapy. The discovery of new cases decreased, especially during the early stages of the pandemic, due to the healthcare systems' strong concentration on controlling the COVID-19 pandemic, a considerable drop in the number of diagnostic procedures, and a dip in procedures such as skin lesion biopsies.

Additionally, the COVID-19 pandemic is providing serious challenges for industry players in the global basal cell carcinoma market on a number of fronts. One of the biggest problems caused by transportation irregularities is the availability of raw materials required to produce pharmaceutical formulations. Additionally, due of an increase in patients with COVID-19 and other life-threatening disorders, distributors are witnessing unpredictable demand for their products from retailers.

Segment Analysis

The surgical excision segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The treatment segment is the highest market holder in the global basal cell carcinoma treatment market. Surgical excision is the most widely utilized treatment for basal cell carcinoma. The surgeon removes the malignant tumor together with a margin of good skin during this surgery. To ensure no cancer cells are present, the surplus is examined using a microscope. For basal cell carcinomas that are less prone to recur, such as those that develop on the chest, back, hands, and feet, excision may be advised.

Due to its lowest possible recurrence rates, highest possible cure rates, and best cosmetic outcomes among all treatment approaches for basal cell carcinoma, and surgical excision has proven to be more effective, leading to its high demand. Surgical removal with a 2-3-mm excision margin is an appropriate treatment with a 99% removal success rate for well-defined, primary-pigmented BCC.

The most popular kinds of skin cancer, basal cell carcinomas (BCCs) and squamous cell carcinomas (SCCs), are frequently treated with Mohs surgery. The process, known as Mohs micrographic surgery, is carried out in phases while the patient waits and includes lab testing. All malignant cells can be removed while sparing healthy tissue and leaving the lowest scar feasible to maximize the chance of curing cancer. Out of all available treatments, Mohs micrographic surgery has the highest success rate in curing basal cell and squamous cell skin malignancies. The cure rate for basal cell carcinoma is up to 99% for newly diagnosed patients and up to 94% for recurring cases. Over the next few, it is anticipated that surgical excision, followed by Mohs micrographic, will continue to dominate, reiterating the surgical segment's predominance.

Geographical Analysis

North America holds the largest market share in the global Basal Cell Carcinoma Treatment market.

North America dominates the global basal cell carcinoma treatment market primarily due to its large population, excellent medical infrastructure, and high-income levels. North America is anticipated to dominate the basal cell carcinoma treatment market throughout the forecast period. This is because of the rising incidence of the elderly population, increased knowledge of cutting-edge treatments, a favorable reimbursement environment, and the high frequency of basal cell carcinoma in this area.

According to the Centers for Disease Control and Prevention (CDC), there will be 3 to 4 million cases of non-melanoma skin cancer in the United States in 2020. This contributes to a larger patient base that needs the treatment. More individuals need medicine due to the rising prevalence of advanced basal cell carcinoma and Squamous cell carcinoma instances. Additionally, the region's growth is fueled by an increase in the number of new pharmaceuticals in the U.S. receiving regulatory approval.

For instance, in February 2021, As the first immunotherapy for patients with advanced basal cell carcinoma (BCC) who have not previously received a hedgehog pathway inhibitor (HHI) or for whom an HHI is not appropriate, the PD-1 inhibitor Libtayo (cemiplimab-rwlc) got FDA approval. Patients with locally advanced BCC received full approval, whereas those with metastatic BCC received accelerated approval. Additionally, the fact that Genetech and AiViva Biopharma International are conducting clinical trials to create novel therapeutics for basal cell carcinoma is likely to lead to an increase in the number of new product launches in the near term, which is also anticipated to fuel market growth.

Competitive Landscape

The Basal Cell Carcinoma Treatment market is moderately competitive with local and global companies' presence Sun Pharmaceuticals Ltd., Merck & Co., Inc., Valeant Pharmaceuticals International, Inc., Regeneron Pharmaceuticals Inc, Hoffmann-La Roche Ltd., Mylan N.V., Perrigo Company, Strides Arcolab Ltd, AiViva Bio Pharma, Inc and Allergan Inc

The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the market's growth. For instance, in December 2022, in a Phase I/II study to assess the safety and effectiveness of MW005 in the treatment of low-risk basal cell carcinoma, MediWound Ltd, a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today reported encouraging results (BCC).

Sun Pharmaceutical Industries, Inc.

Overview: An extensive selection of pharmaceutical formulations, including branded generics and generic medications, are offered by Sun Pharmaceutical Industries Ltd. (Sun Pharma), a speciality pharmaceutical company. Products for the treatment of psychiatric, neurological, nephrological, gastroenterological, orthopedic, and ophthalmologic diseases and disorders, as well as cardiac problems, are part of the company's portfolio.

Product Portfolio:

ODOMZO: It is a (sonidegib) is a prescription medicine used to treat adults with a type of skin cancer, called basal cell carcinoma, that has come back following surgery or radiation or that cannot be treated with surgery or radiation..

The global Basal Cell Carcinoma Treatment market report would provide access to approx.: 45+market data table, 40+figures and 200 (approximate) pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The market is predicted to grow as skin cancers become more common
      • 4.1.1.2. Product approval for basal cell carcinoma therapy
    • 4.1.2. Restraints:
      • 4.1.2.1. Lack of skilled experts, that which hampers the market
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1 Porter's Five Forces Analysis
  • 5.2 Supply Chain Analysis
  • 5.3 Pricing Analysis
  • 5.4 Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Treatment Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 7.1.2. Market Attractiveness Index, By Treatment Type
  • 7.2. Surgical
      • 7.2.1.1. Surgical Excision
      • 7.2.1.2. Electrodessication & Cutterage ED&C
      • 7.2.1.3. Moh's Surgery and Cryosurgery
    • 7.2.2. Introduction
    • 7.2.3. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Drugs
      • 7.3.1.1. Topical Treatment
      • 7.3.1.2. Advanced Medication
      • 7.3.1.3. Others
  • 7.4. Therapy
      • 7.4.1.1. Radiation Therapy
      • 7.4.1.2. Photodynamic Therapy
      • 7.4.1.3. Laser Therapy

8. By End user

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End user
    • 8.1.2. Market Attractiveness Index, By End user
  • 8.2. Hospitals
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Specialty Clinics
  • 8.4. Others

9. By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End user
    • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.2.5.1. U.S.
      • 9.2.5.2. Canada
      • 9.2.5.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End user
    • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.3.5.1. Germany
      • 9.3.5.2. U.K.
      • 9.3.5.3. France
      • 9.3.5.4. Italy
      • 9.3.5.5. Spain
      • 9.3.5.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End user
    • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.4.5.1. Brazil
      • 9.4.5.2. Argentina
      • 9.4.5.3. Rest of South America
  • 9.5. Asia Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End user
    • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.5.5.1. China
      • 9.5.5.2. India
      • 9.5.5.3. Japan
      • 9.5.5.4. Australia
      • 9.5.5.5. Rest of Asia Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End user

10. Competitive Landscape

  • 10.1. Key Developments and Strategies
  • 10.2. Company Share Analysis
  • 10.3. Products Benchmarking
  • 10.4. List of Key Companies to Watch

11. Company Profiles

  • 11.1. Sun Pharmaceutical Industries, Inc
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Key Highlights
    • 11.1.4. Financial Overview
  • 11.2. Sun Pharmaceuticals Ltd.
  • 11.3. Merck & Co., Inc.
  • 11.4. Valeant Pharmaceuticals International, Inc.
  • 11.5. Regeneron Pharmaceuticals Inc
  • 11.6. Hoffmann-La Roche Ltd.
  • 11.7. Mylan N.V.
  • 11.8. Perrigo Company
  • 11.9. Strides Arcolab Ltd
  • 11.10. AiViva Bio Pharma, Inc
  • 11.11. Sanofi

LIST NOT EXHAUSTIVE

12. Global Basal Cell Carcinoma Treatment Market - DataM

  • 12.1. Appendix
  • 12.2. About Us and Application
  • 12.3. Contact Us